Yuan Shaozhan, Shi Haiyan, Cui Yong, Liu Yan, Cai Meizhi, Huang Yifan
Department of Blood Transfusion, Zibo First Hospital, Zibo, China.
Department of Internal Medicine II, Zibo First Hospital Branch, Zibo, China.
Sci Rep. 2024 Dec 2;14(1):29900. doi: 10.1038/s41598-024-78978-z.
Multidrug-resistant tuberculosis (MDR-TB) remains a global public health challenge. We aimed to investigate the utility of combining the cardiometabolic index (CMI) and systemic inflammation response index (SIRI) as biomarkers for rapid MDR-TB screening. Data were collected from 2,620 TB patients in Zibo city from 2018 to 2021. Logistic regression and receiver operating characteristic (ROC) curve analyses were used to evaluate the associations and diagnostic performance of CMI and SIRI with MDR-TB. The prevalence of MDR-TB was 5.0% in new TB patients and 20.5% in recurrent TB patients. Both CMI and SIRI were significantly associated with MDR-TB in all models (P < 0.05). In new TB patients, the area under the curve (AUC) values of the ROC curves for SIRI, CMI, and their combination were 0.845, 0.806, and 0.910, respectively. In recurrent TB patients, the AUC values were 0.730, 0.875, and 0.902, respectively. The optimal cut-off points for SIRI and CMI were 0.72 and 1.81 in new TB patients, and 1.05 and 1.48 in recurrent TB patients, respectively. In conclusion, combining CMI and SIRI shows promise as a low-invasive, cost-effective tool for early MDR-TB screening, warranting further validation in diverse populations and TB subtypes.
耐多药结核病（MDR-TB）仍然是一项全球公共卫生挑战。我们旨在研究将心脏代谢指数（CMI）和全身炎症反应指数（SIRI）结合作为快速筛查耐多药结核病生物标志物的效用。收集了2018年至2021年淄博市2620例结核病患者的数据。采用逻辑回归和受试者工作特征（ROC）曲线分析来评估CMI和SIRI与耐多药结核病的相关性及诊断性能。新结核病患者中耐多药结核病的患病率为5.0%，复发性结核病患者中为20.5%。在所有模型中，CMI和SIRI均与耐多药结核病显著相关（P<0.05）。在新结核病患者中，SIRI、CMI及其组合的ROC曲线下面积（AUC）值分别为0.845、0.806和0.910。在复发性结核病患者中，AUC值分别为0.730、0.875和0.902。新结核病患者中SIRI和CMI的最佳截断点分别为0.72和1.81，复发性结核病患者中分别为1.05和1.48。总之，将CMI和SIRI结合作为一种低侵入性、成本效益高的早期耐多药结核病筛查工具显示出前景，值得在不同人群和结核病亚型中进一步验证。
